1 |
Nam HJ, Song MY, Choi DH, Yang SH, Jin HT and Sung YC (2010) Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant. Eur J Immunol 40, 351-358
DOI
|
2 |
Mortara L, Balza E, Bruno A, Poggi A, Orecchia P and Carnemolla B (2018) Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol 9, 2905
DOI
|
3 |
Ishihara J, Ishihara A, Sasaki K et al (2019) Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci Transl Med 11, eaau3259
DOI
|
4 |
Mostbock S (2009) Cytokine/Antibody complexes: an emerging class of immunostimulants. Curr Pharm Des 15, 809-825
DOI
|
5 |
Kamimura D, Sawa Y, Sato M, Agung E, Hirano T and Murakami M (2006) IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 177, 306-314
DOI
|
6 |
Jin GH, Hirano T and Murakami M (2008) Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Int Immunol 20, 783-789
DOI
|
7 |
Roopenian DC and Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7, 715-725
DOI
|
8 |
Zhu EF, Gai SA, Opel CF et al (2015) Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27, 489-501
DOI
|
9 |
Sun Z, Ren Z, Yang K et al (2019) A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8(+) T-cell response and effective tumor control. Nat Commun 10, 3874
DOI
|
10 |
Guimond M, Veenstra RG, Grindler DJ et al (2009) Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat Immunol 10, 149-157
DOI
|
11 |
Al-Shami A, Spolski R, Kelly J et al (2004) A role for thymic stromal lymphopoietin in CD4(+) T cell development. J Exp Med 200, 159-168
DOI
|
12 |
Peschon JJ, Morrissey PJ, Grabstein KH et al (1994) Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 180, 1955-1960
DOI
|
13 |
von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE and Murray R (1995) Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 181, 1519-1526
DOI
|
14 |
Clark MR, Mandal M, Ochiai K and Singh H (2014) Orchestrating B cell lymphopoiesis through interplay of IL-7 receptor and pre-B cell receptor signalling. Nat Rev Immunol 14, 69-80
DOI
|
15 |
Puel A, Ziegler SF, Buckley RH and Leonard WJ (1998) Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet 20, 394-397
DOI
|
16 |
Mazzucchelli R and Durum SK (2007) Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 7, 144-154
DOI
|
17 |
Kondo M, Akashi K, Domen J, Sugamura K and Weissman IL (1997) Bcl-2 rescues T lymphopoiesis, but not B or NK cell development, in common gamma chain-deficient mice. Immunity 7, 155-162
DOI
|
18 |
Akashi K, Kondo M, von Freeden-Jeffry U, Murray R and Weissman IL (1997) Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89, 1033-1041
DOI
|
19 |
Maraskovsky E, O'Reilly LA, Teepe M, Corcoran LM, Peschon JJ and Strasser A (1997) Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1(-/-) mice. Cell 89, 1011-1019
DOI
|
20 |
Yang JC, Topalian SL, Schwartzentruber DJ et al (1995) The use of polyehylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. Cancer 76, 687-694
DOI
|
21 |
Cui GL, Staron MM, Gray SM et al (2015) IL-7-induced glycerol transport and TAG synthesis promotes memory CD8(+) T cell longevity. Cell 161, 750-761
DOI
|
22 |
Choi YW, Kang MC, Seo YB et al (2016) Intravaginal administration of Fc-fused IL7 suppresses the cervicovaginal tumor by recruiting HPV DNA vaccine-induced CD8 T cells. Clin Cancer Res 22, 5898-5908
DOI
|
23 |
Kim JH, Kim YM, Choi D et al (2020) Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy. Clin Transl Immunology 9, e1168
|
24 |
Wofford JA, Wieman HL, Jacobs SR, Zhao Y and Rathmell JC (2008) IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood 111, 2101-2111
DOI
|
25 |
Kimura MY, Pobezinsky LA, Guinter TI et al (2013) IL-7 signaling must be intermittent, not continuous, during CD8 (+) T cell homeostasis to promote cell survival instead of cell death. Nat Immunol 14, 143-151
DOI
|
26 |
Rosenberg SA, Sportes C, Ahmadzadeh M et al (2006) IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29, 313-319
DOI
|
27 |
Leonard WJ, Lin JX and O'Shea JJ (2019) The gammac family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832-850
DOI
|
28 |
Pellegrini M, Bouillet P, Robati M, Belz GT, Davey GM and Strasser A (2004) Loss of Bim increases T cell production and function in interleukin 7 receptor-deficient mice. J Exp Med 200, 1189-1195
DOI
|
29 |
Khaled AR, Li WQ, Huang J et al (2002) Bax deficiency partially corrects interleukin-7 receptor alpha deficiency. Immunity 17, 561-573
DOI
|
30 |
Menetrier-Caux C, Ray-Coquard I, Blay JY and Caux C (2019) Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer 7, 85
DOI
|
31 |
Morgan DA, Ruscetti FW and Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193, 1007-1008
DOI
|
32 |
Boyman O and Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12, 180-190
DOI
|
33 |
Wang X, Rickert M and Garcia KC (2005) Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310, 1159-1163
DOI
|
34 |
Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22, 531-562
DOI
|
35 |
Sportes C, Hakim FT, Memon SA et al (2008) Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 205, 1701-1714
DOI
|
36 |
Tredan O, Menetrier-Caux C, Ray-Coquard I et al (2015) ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. Ann Oncol 26, 1353-1362
DOI
|
37 |
Lee SW, Choi D, Heo M et al (2020) hIL-7-hyFc, a longacting IL-7, increased absolute lymphocyte count in healthy subjects. Clin Transl Sci 13, 1161-1169
DOI
|
38 |
Zhang X, Sun S, Hwang I, Tough DF and Sprent J (1998) Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8, 591-599
DOI
|
39 |
Boyman O, Kovar M, Rubinstein MP, Surh CD and Sprent J (2006) Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924-1927
DOI
|
40 |
Chen DS and Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10
DOI
|
41 |
Miller PW, Sharma S, Stolina M et al (2000) Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther 11, 53-65
DOI
|
42 |
Merchant MS, Bernstein D, Amoako M et al (2016) Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res 22, 3182-3191
DOI
|
43 |
Reimers MA, Slane KE and Pachynski RK (2019) Immunotherapy in metastatic castration-resistant prostate cancer: past and future strategies for optimization. Curr Urol Rep 20, 64
DOI
|
44 |
Sportes C, Babb RR, Krumlauf MC et al (2010) Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 16, 727-735
DOI
|
45 |
Li B, VanRoey MJ and Jooss K (2007) Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy. Clin Immunol 123, 155-165
DOI
|
46 |
Laurence A, Tato CM, Davidson TS et al (2007) Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26, 371-381
DOI
|
47 |
Liao W, Lin JX, Wang L, Li P and Leonard WJ (2011) Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol 12, 551-559
DOI
|
48 |
Yang XP, Ghoreschi K, Steward-Tharp SM et al (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12, 247-254
DOI
|
49 |
Liao W, Spolski R, Li P et al (2014) Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression. Proc Natl Acad Sci U S A 111, 3508-3513
DOI
|
50 |
Ballesteros-Tato A, Leon B, Graf BA et al (2012) Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 36, 847-856
DOI
|
51 |
Martin CE, van Leeuwen EM, Im SJ, Roopenian DC, Sung YC and Surh CD (2013) IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R. Blood 121, 4484-4492
DOI
|
52 |
Pellegrini M, Calzascia T, Elford AR et al (2009) Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 15, 528-536
DOI
|
53 |
Andersson A, Srivastava MK, Harris-White M et al (2011) Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer. Clin Cancer Res 17, 3660-3672
DOI
|
54 |
Boyman O, Ramsey C, Kim DM, Sprent J and Surh CD (2008) IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T cell expansion without lymphopenia. J Immunol 180, 7265-7275
DOI
|
55 |
Boudil A, Matei IR, Shih HY et al (2015) IL-7 coordinates proliferation, differentiation and Tcra recombination during thymocyte beta-selection. Nat Immunol 16, 397-405
DOI
|
56 |
Fridman WH, Pages F, Sautes-Fridman C and Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12, 298-306
DOI
|
57 |
Sadlack B, Lohler J, Schorle H et al (1995) Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25, 3053-3059
DOI
|
58 |
Willerford DM, Chen J, Ferry JA, Davidson L, Ma A and Alt FW (1995) Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530
DOI
|
59 |
Suzuki H, Kundig TM, Furlonger C et al (1995) Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268, 1472-1476
DOI
|
60 |
Almeida AR, Legrand N, Papiernik M and Freitas AA (2002) Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 169, 4850-4860
DOI
|
61 |
Swainson L, Kinet S, Mongellaz C, Sourisseau M, Henriques T and Taylor N (2007) IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 109, 1034-1042
DOI
|
62 |
Moore TA, von Freeden-Jeffry U, Murray R and Zlotnik A (1996) Inhibition of gamma delta T cell development and early thymocyte maturation in IL-7 -/- mice. J Immunol 157, 2366-2373
|
63 |
Shitara S, Hara T, Liang B et al (2013) IL-7 produced by thymic epithelial cells plays a major role in the development of thymocytes and TCRgammadelta+ intraepithelial lymphocytes. J Immunol 190, 6173-6179
DOI
|
64 |
Vosshenrich CA, Garcia-Ojeda ME, Samson-Villeger SI et al (2006) A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat Immunol 7, 1217-1224
DOI
|
65 |
Vogt TK, Link A, Perrin J, Finke D and Luther SA (2009) Novel function for interleukin-7 in dendritic cell development. Blood 113, 3961-3968
DOI
|
66 |
Soares MV, Borthwick NJ, Maini MK, Janossy G, Salmon M and Akbar AN (1998) IL-7-dependent extrathymic expansion of CD45RA+ T cells enables preservation of a naive repertoire. J Immunol 161, 5909-5917
|
67 |
Ernst B, Lee DS, Chang JM, Sprent J and Surh CD (1999) The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity 11, 173-181
DOI
|
68 |
Goldrath AW and Bevan MJ (1999) Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 11, 183-190
DOI
|
69 |
Surh CD and Sprent J (2008) Homeostasis of naive and memory T cells. Immunity 29, 848-862
DOI
|
70 |
Surh CD and Sprent J (2005) Regulation of mature T cell homeostasis. Semin Immunol 17, 183-191
DOI
|
71 |
Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ and Rao A (2010) Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 32, 79-90
DOI
|
72 |
Malek TR, Yu A, Vincek V, Scibelli P and Kong L (2002) CD4 regulatory T cells prevent lethal autoimmunity in IL-2 Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17, 167-178
DOI
|
73 |
Fontenot JD, Rasmussen JP, Gavin MA and Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6, 1142-1151
DOI
|
74 |
Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA and Ahmed R (2010) Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 32, 91-103
DOI
|
75 |
Lenardo M, Chan KM, Hornung F et al (1999) Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17, 221-253
DOI
|
76 |
Rosenberg SA, Lotze MT, Muul LM et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313, 1485-1492
DOI
|
77 |
Atkins MB, Lotze MT, Dutcher JP et al (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17, 2105-2116
DOI
|
78 |
Rosenberg SA, Lotze MT, Aebersold PM, Linehan WM, Seipp CA and White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210, 474-485
DOI
|
79 |
Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913
DOI
|
80 |
Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR and Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13, 688-696
DOI
|
81 |
Caligiuri MA, Murray C, Robertson MJ et al (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91, 123-132
DOI
|
82 |
Caligiuri MA, Murray C, Soiffer RJ et al (1991) Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol 9, 2110-2119
DOI
|
83 |
Soiffer RJ, Murray C, Shapiro C et al (1996) Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res 2, 493-499
|
84 |
Fehniger TA, Bluman EM, Porter MM et al (2000) Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 106, 117-124
DOI
|
85 |
Wrangle JM, Patterson A, Johnson CB et al (2018) IL-2 and beyond in cancer immunotherapy. J Interferon Cytokine Res 38, 45-68
DOI
|
86 |
Krieg C, Letourneau S, Pantaleo G and Boyman O (2010) Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 107, 11906-11911
DOI
|
87 |
Sim GC, Martin-Orozco N, Jin L et al (2014) IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 124, 99-110
DOI
|
88 |
Levin AM, Bates DL, Ring AM et al (2012) Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529-533
DOI
|
89 |
Ardolino M, Azimi CS, Iannello A et al (2014) Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 124, 4781-4794
DOI
|
90 |
Hennion-Tscheltzoff O, Leboeuf D, Gauthier SD et al (2013) TCR triggering modulates the responsiveness and homeostatic proliferation of CD4+ thymic emigrants to IL-7 therapy. Blood 121, 4684-4693
DOI
|
91 |
Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA and Boussiotis VA (2004) Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 200, 659-669
DOI
|
92 |
Park JH, Adoro S, Lucas PJ et al (2007) 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol 8, 1049-1059
DOI
|
93 |
Seddiki N, Santner-Nanan B, Martinson J et al (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203, 1693-1700
DOI
|
94 |
Liu W, Putnam AL, Xu-Yu Z et al (2006) CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203, 1701-1711
DOI
|
95 |
Charych DH, Hoch U, Langowski JL et al (2016) NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor Models. Clin Cancer Res 22, 680-690
DOI
|
96 |
Sharma M, Khong H, Fa'ak F et al (2020) Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun 11, 661
DOI
|
97 |
Mackall CL, Fry TJ and Gress RE (2011) Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 11, 330-342
DOI
|
98 |
Link A, Vogt TK, Favre S et al (2007) Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol 8, 1255-1265
DOI
|
99 |
Kim GY, Hong C and Park JH (2011) Seeing is believing: illuminating the source of in vivo interleukin-7. Immune Netw 11, 1-10
DOI
|